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Abstract
Introduction: Thromboelastometry (TEM)-guided haemostatic therapy with fibrinogen concentrate and
prothrombin complex concentrate (PCC) in trauma patients may reduce the need for transfusion of red blood cells
(RBC) or platelet concentrate, compared with fresh frozen plasma (FFP)-based haemostatic therapy.
Methods: This retrospective analysis compared patients from the Salzburg Trauma Centre (Salzburg, Austria)
treated with fibrinogen concentrate and/or PCC, but no FFP (fibrinogen-PCC group, n = 80), and patients from the
TraumaRegister DGU receiving ≥ 2 units of FFP, but no fibrinogen concentrate/PCC (FFP group, n = 601). Inclusion
criteria were: age 18-70 years, base deficit at admission ≥2 mmol/L, injury severity score (ISS) ≥16, abbreviated
injury scale for thorax and/or abdomen and/or extremity ≥3, and for head/neck < 5.
Results: For haemostatic therapy in the emergency room and during surgery, the FFP group (ISS 35.5 ± 10.5)
received a median of 6 units of FFP (range: 2, 51), while the fibrinogen-PCC group (ISS 35.2 ± 12.5) received
medians of 6 g of fibrinogen concentrate (range: 0, 15) and 1200 U of PCC (range: 0, 6600). RBC transfusion was
avoided in 29% of patients in the fibrinogen-PCC group compared with only 3% in the FFP group (P< 0.001).
Transfusion of platelet concentrate was avoided in 91% of patients in the fibrinogen-PCC group, compared with
56% in the FFP group (P< 0.001). Mortality was comparable between groups: 7.5% in the fibrinogen-PCC group
and 10.0% in the FFP group (P = 0.69).
Conclusions: TEM-guided haemostatic therapy with fibrinogen concentrate and PCC reduced the exposure of
trauma patients to allogeneic blood products.
Introduction
In patients with severe trauma, coagulopathy represents
a frequent cause of death [1,2]. Prompt haemostatic
intervention is necessary to prevent and correct life-
threatening bleeding. Standard coagulation therapy con-
sists of fresh frozen plasma (FFP), platelet concentrate
and, in some countries, cryoprecipitate [3,4]. One
approach proposed for preventing exsanguination has
been to treat patients with a fixed ratio of FFP to red
blood cells (RBC), but the optimal value of this ratio is
still under debate [5-8]. It has been recently suggested
that the time to intervention may also be an important
determinant of patient outcomes [9,10].
Our group has been exploring goal-directed coagula-
tion management using fibrinogen concentrate and pro-
thrombin complex concentrate (PCC), administered as
early as possible according to thromboelastometric
(TEM) measurements [11,12]. This approach supports
timely and aggressive correction of coagulopathy. It may
also be considered as a strategy for reducing transfusion
of allogeneic blood products: the need for FFP may be
reduced by the administration of coagulation factors:
fibrinogen, contained in fibrinogen concentrate, and fac-
tors II, VII, IX and X, contained in most PCCs. Further-
more, clinical and experimental data suggest that
fibrinogen supplementation may also compensate for
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any medium, provided the original work is properly citedreduced platelet count [13,14]. Supplementation of fibri-
nogen may support primary haemostasis, because fibri-
nogen facilitates platelet aggregation by bridging platelet
glycoprotein IIb/IIIa receptors [15]. In addition, the use
of fibrinogen concentrate leads to increased firmness of
the fibrin-based clot [16], whereas PCC administration
may correct prolonged coagulation times through
improved thrombin generation [17].
We recently reported favourable outcomes in major
trauma patients referred to our level 1 trauma centre
and treated following TEM-guided haemostatic therapy
with fibrinogen concentrate and PCC [12]. Observed
mortality in this retrospective analysis was lower than
that predicted by the Revised Injury Severity Classifica-
tion Score (RISC) [18] and Trauma Injury Severity
Score (TRISS) [19]. The treatment strategy eliminated
time delays associated with standard coagulation testing
and preparation of allogeneic blood products for trans-
fusion: more than half of the patients received haemo-
static therapy within an hour of admission to the
emergency room (ER). Furthermore, the low transfusion
rates suggested that TEM-guided haemostatic therapy
with fibrinogen concentrate and PCC may reduce the
use of allogeneic blood products in trauma patients.
In the present retrospective study, we compared two dif-
ferent concepts of haemostatic therapy in major trauma
patients: TEM-guided haemostatic therapy with fibrinogen
concentrate and PCC versus FFP-based therapy. Patients
receiving coagulation factor concentrates were treated at
the Salzburg Trauma Centre (STC; Salzburg, Austria).
Those receiving FFP-based therapy were selected from the
trauma registry of the German Society for Trauma Surgery
(TR-DGU), which includes 161 trauma hospitals, mostly
in Germany, and holds details of a very large number of
patients treated with standard coagulation therapy. We
hypothesised that transfusion of RBC and platelet concen-
trate is lower in patients receiving TEM-guided haemo-
static therapy with fibrinogen concentrate and PCC,
compared with patients receiving FFP-based therapy.
We hypothesised that TEM-guided haemostatic ther-
apy with fibrinogen concentrate and PCC may lead to
increased avoidance of RBC and platelet concentrate
transfusion compared with FFP-based therapy.
Materials and methods
Fibrinogen-PCC group (Salzburg Trauma Centre)
Following local ethics committee approval, we per-
formed a retrospective analysis of transfusion para-
meters in major trauma patients who were admitted to
the STC from 2006 to 2009 and treated with fibrinogen
concentrate and PCC according to TEM
® analyses, per-
formed using ROTEM
® (Tem International, Munich,
Germany) as previously described by Schöchl et al [12].
Demographic data, laboratory data, trauma scores and
outcomes data were obtained from the electronic data-
base that was used for recording ER therapy and from
the ICU database.
FFP group (TR-DGU)
The TR-DGU is a repository for prospective, standar-
dised and anonymous documentation of data on
severely injured patients requiring ICU treatment [6]. At
the beginning of 2010, TR-DGU contained data from
more than 42,000 patients. Patients treated between
2005 and 2008 were included in the present study. As
described elsewhere [6], the registry includes informa-
tion on demographics, injury severity and pattern, pre-
and in-hospital management, laboratory findings, time
course and the outcome for each patient.
Inclusion and exclusion criteria
Inclusion criteria for both groups of patients were: age
between 18 and 70 years, injury severity score (ISS) of
16 or more, base deficit at admission or 2 mmol/L or
higher, abbreviated injury scale (AIS) for thorax and/or
abdomen and/or extremity of 3 or more and AIS for
head/neck less than 5 (Table 1). Furthermore, only
patients with all information needed to calculate TRISS
and RISC scores were included.
For the fibrinogen-PCC group, patients who received
fibrinogen (≥1 g) and/or PCC (≥500 U) but no FFP were
included. For the FFP group, patients who received at
least 2 units of FFP but no fibrinogen concentrate or
PCC were included.
Coagulation management
In the fibrinogen-PCC group, coagulation management
was guided by TEM analysis [12]. Haemostatic therapy
comprised administration of 2 to 4 g of fibrinogen con-
centrate (first-line therapy for patients needing increased
firmness of the fibrin-based clot), and administration of
1,000 to 1,500 U of PCC, for patients showing pro-
longed clotting time in the thromboelastometry EXTEM
test (> 1.5 times normal) [12]. This treatment was
repeated as necessary. Fibrinogen concentrate was admi-
nistered using two to four automatic infusion systems
(Perfusor
®,B .B r a u n ,M e l s u n g e n ,G e r m a n y )w o r k i n gi n
parallel, each at a rate of 200 mL/h; for each infusion
system, 1 g of fibrinogen concentrate was diluted in 50
mL of water for injections. The resulting administration
rate was 2 to 4 g in 15 minutes. For patients in whom
fibrinogen could not fully compensate for decreased pla-
telet levels, platelet concentrate was transfused (platelet
concentrate was recommended if the EXTEM-MCF is
decreased to < 40 mm when FIBTEM-MCF is 10 to 12
mm). The target haemoglobin concentration during the
operative procedure was 10 g/dL. In the postoperative
phase, lower haemoglobin levels were tolerated.
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was dictated by clinical practice at each trauma depart-
ment and was therefore not standardised. TEM is not
used in standard practice; nevertheless, isolated use in
some hospitals means that a minority of patients in the
registry may have been treated with some TEM gui-
dance. Although the treatment of patients in the TR-
DGU is not standardised, it represents the general
approach to coagulation management of major trauma
patients in Germany, with FFP administered as first-line
haemostatic therapy, and platelet concentrate and RBC
used as necessary. Laboratory analyses of coagulation
were performed in the local laboratories; the register
collects no information on the type of analyses, reagents
or devices on which they are performed, or on their role
in guiding haemostatic therapy within the local protocol.
Selection of variables for analysis
For all subjects, age and gender were documented
together with the following parameters upon admission:
coagulation results, blood pressure, heart rate, tempera-
ture, ISS and Glasgow coma scale score. Predicted mor-
tality for each patient was estimated using the RISC and
the TRISS methodology. Mortality rate (until discharge
from the hospital) was documented.
Details of coagulation management were noted for the
acute phase (ER and early surgery phase) and the first
48 hours spent in the ICU. For the fibrinogen-PCC
group, administration of RBC, fibrinogen concentrate,
PCC and platelet concentratew e r en o t e df o rb o t ht i m e
periods. For the FFP group, administration of RBC and
FFP were noted for both time periods; data for platelet
concentrate administration were only available for the
acute phase.
Statistical analysis
Demographic and clinical data were presented as mean
± standard deviation or median (minimum, maximum
or interquartile range (IQR), as indicated) for continu-
ous variables, and as percentages for categorical vari-
ables. For continuous variables, normal distribution was
analysed by the Shapiro-Wilk test. To detect differences
between the patient groups, either the Student’s t-test or
the Mann-Whitney U test was performed, depending on
the underlying distribution. For categorical variables,
Fisher’s exact test was used. Statistics were calculated
using IBM SPSS Statistics 18 (SPSS Inc., Chicago, IL,
USA).
Results
In the fibrinogen-PCC group, 80 of 353 patients treated
in the STC between 2005 and 2009 fulfilled the inclu-
sion criteria. Between 2005 and 2008 (data for 2009
were not available at the time of analysis), 21,263
patients were included in the TR-DGU. Of 21,263
patients, 2,582 fulfilled the general inclusion criteria. At
this step, most cases were lost due to missing base defi-
cit values. After applying the specific haemostatic ther-
apy criteria (Table 1), 601 patients could be included in
the FFP group.
Demographic data and trauma scores were available
for all patients included in the study. As intended, the
two groups were comparable with regard to demo-
graphic parameters as well as the overall magnitude of
injury sustained and probability of survival assessed by
the TRISS and RISC scores (Table 2). With regard to
the pattern of injury, patients in the FFP group had sus-
tained head and thoracic injuries of higher magnitude,
whereas fibrinogen-PCC patients had sustained more
severe abdominal injuries. Patients in the fibrinogen-
PCC group also appeared to be less haemodynamically
stable upon arrival at the ER. Standard laboratory coa-
gulation data were available for at least 90% of the
patients included in the study. A significantly more pro-
longed prothrombin time (PT) was observed in the fibri-
nogen-PCC group (P = 0.0001; Table 3); this difference
Table 1 Inclusion criteria
Fibrinogen-PCC group
(Salzburg Trauma Centre)
FFP group (TR-DGU)
Type of therapy ROTEM-guided administration of coagulation factor concentrates According to local protocols
ISS ≥ 16
AIS thorax, abdomen, extremities At least in one region, one injury with severity degree ≥3, AIShead/neck <5
Age (years) 18-70
Base deficit at admission ≥2 mmol/L
FFP administered No FFP ≥2 units FFP
Fibrinogen/PCC administered ≥1 g fibrinogen; ≥ 500 U PCC No fibrinogen or PCC
Investigated time period 2005-2009 2005-2008
Patients included in database 353 21263
Patients fulfilling inclusion criteria 80 601
AIS, abbreviated injury scale; FFP, fresh frozen plasma; ISS, injury severity score; n, number of patients; PCC, prothrombin complex concentrate; ROTEM,
thromboelastometry; TR-DGU, trauma registry of the German Society for Trauma Surgery.
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The base deficit also differed between the groups (6.4 ±
3.4 in the fibrinogen-PCC group and 6.9 ± 4.5 mmol/L
in the FFP group), but this difference did not reach sta-
tistical significance.
RBC transfusion data for treatment in the ER and dur-
ing surgery were available for all patients. Complete
avoidance of RBC transfusion was observed in 3% of
patients in the FFP group and 29% of patients in the
fibrinogen-PCC group (P< 0.0001; Figure 1). In the FFP
group, 583 of 601 patients (97%) received RBC transfu-
sion (number of units ranging between 1 and 64), com-
pared with 57 of 80 patients (71%) in the fibrinogen-
PCC group (range: 1 to 28 units). Information on plate-
let concentrate transfusion for treatment in the ER and
during surgery was available for 371 of the 601 patients
in the FFP group, and for all patients in the fibrinogen-
PCC group. Platelet concentrate was administered to
44% of patients in the FFP group, compared with 9% in
the fibrinogen-PCC group (P = 0.0001; Figure 1). Of
interest, all patients with no transfusion of RBC also did
not receive any platelet concentrate, meaning total
avoidance of allogeneic blood products in 29% of the
patients in the fibrinogen-PCC group.
For haemostatic therapy in the ER and during surgery,
the FFP group received a median of 6 units of FFP
(IQR: 4, 10; range: 2, 51), 6 units of RBC (IQR: 4, 11)
and 0 units of platelet concentrate (IQR: 0, 2; range: 0,
8). The patients in the fibrinogen-PCC group received a
median of 6 g of fibrinogen concentrate (IQR: 3, 9;
range: 0, 15) and 1,200 IU of PCC (IQR: 0, 2,400; range:
0, 6,600), while RBC median transfusion was 5.5 units
(IQR: 0, 9.5) and platelet concentrate median transfu-
s i o nw a s0u n i t s( I Q R :0 ,0 ;r a n g e :0 ,2 ) .T h ed o s a g eo f
FFP, fibrinogen and PCC is described in Figure 2. Dur-
ing the first 48 hours after admission to the ICU,
patients in the FFP group received median doses of 3
units of RBC (IQR: 1, 6; range: 0, 80; data reported for
Table 2 Patient demographic and clinical data
Fibrinogen-PCC group (n = 80) FFP group (n = 601)
Age (years) 37.3 ± 14.5 39.1 ± 14.5
Male n (%) 63 (79) 442 (74)
Systolic blood pressure on admission at ER (mmHg) 95 ± 30 108 ± 30**
Heart rate on admission at ER (beats/minute) 105 ± 26 99 ± 24*
ISS 35.5 ± 10.5 35.2 ± 12.5
GCS 12.2 ± 3.4 11.3 ± 4.4*
AIS Head 1.1 ± 1.5 1.6 ± 1.7*
AIS Chest 2.1 ± 2.0 3.1 ± 1.7**
AIS Abdomen 2.5 ± 2.1 2.1 ± 1.8
AIS Extremity 2.9 ± 1.8 2.9 ± 1.4
TASH 13.9 ± 6 12.6 ± 5*
RISC 6.9 (2.4, 16.2) 8.5 (3.3, 24.8)
TRISS 13 (3, 38) 7 (2, 38)
Death 6 (7.5) 60 (10)
Data are presented as mean ± standard deviation, median (interquartile range) or as absolute and relative frequency.
*P< 0.05, significantly different than the fibrinogen-PCC group;
**P = 0.0001, significantly different than the fibrinogen-PCC group.
AIS, abbreviated injury score; ER, emergency room; FFP, fresh frozen plasma; n, number of patients; GCS, Glasgow coma scale; ISS, injury severity score; PCC,
prothrombin complex concentrate; RISC, revised injury severity classification; TASH, trauma associated severe haemorrhage score; TRISS, trauma injury severity
score.
Table 3 Standard laboratory parameters
Admission in the emergency room Arrival at the ICU
Fibrinogen-PCC group
(n = 80)
FFP group
(n = 601)
Fibrinogen-PCC group
(n = 80)
FFP group
(n = 601)
Haemoglobin (13.5-17 g/dL) 9.9 ± 3.1 9.6 ± 2.6 9.6 ± 2.1 9.7 ± 1.9
Platelet count (150-350 *1000 cells/μL) 178 ± 68 184 ± 79 105 ± 58 108 ± 60
Prothrombin time in percentage
(70-110%)
59 ± 19 65 ± 21* 52 ± 16 71 ± 18**
Fibrinogen (2-4.5 g/L) 1.4 ± 0.7 not available 1.8 ± 0.5 not available
Data are presented as mean ± standard deviation; normal range is indicated in parentheses. Data available for at least 90% of patients.
*P< 0.05, significantly different than the fibrinogen-PCC group;
**P = 0.0001, significantly different than the fibrinogen-PCC group. FFP, fresh frozen plasma; n, number of patients; PCC, prothrombin complex concentrate.
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data reported for 405 patients). No information is avail-
able on platelet concentrate transfusion in this group
during the stay on the ICU. For the fibrinogen-PCC
group, a complete set of transfusion data was available.
During their stay at the ICU, these patients received a
median dose of 2 units of RBC (IQR: 0, 3; range: 0, 11),
platelet concentrate was transfused in 9% of the patients
during this time (the dose was 1 or 2 units). The
patients also received a median dose of 6 g of fibrinogen
concentrate (IQR: 3, 10; range: 0, 22) and a median of
1,200 U of PCC (IQR: 0, 2,400; range: 0, 9,000).
For haemostatic therapy in the ER and during surgery,
the median ratio of FFP:RBC in the FFP group was 1
(IQR: 0.7, 1.3; minimum 0.1, maximum 6.5); Figure 3
shows the ratios for all patients in the group. The same
median value was observed in each of the four years
included in the analysis (2005 to 2008). In the fibrino-
gen-PCC group, the median ratio of fibrinogen concen-
trate:RBC for coagulation therapy in the ER and during
surgery was 0.9 (IQR: 0.7, 1.2), and the ratio of PCC (in
hundreds of units):RBC was 1.6 (IQR: 0, 3); Figure 3
shows the distributions of fibrinogen concentrate:RBC
and PCC:RBC ratios.
Data relating to subsequent outcomes were available
for all patients. The median duration of postoperative
intubation was 9.5 days (IQR: 3.5, 14) in the fibrinogen-
PCC group, significantly longer than the 7 days (IQR: 2,
16) in the FFP group (P = 0.005). Median length of stay
(LOS) in the ICU, however, was comparable in the two
g r o u p s :1 4 . 5d a y s( I Q R :8 . 5 ,2 1 )i nt h ef i b r i n o g e n - P C C
group and 14 days (IQR: 6, 23) in the FFP group (P =
0.95). In contrast, the median LOS in the hospital was
significantly different between the two groups: 23 days
(IQR: 14.5, 40.5) in the fibrinogen-PCC group and 32
days (IQR: 20, 49) in the FFP group (P = 0.005). Mortal-
ity was 10.0% in the FFP group and 7.5% in the fibrino-
gen-PCC group (P = 0.69, not significant).
Discussion
The present study compared TEM-guided haemostatic
therapy using fibrinogen concentrate and PCC, with
standard FFP-based therapy, in trauma patients. RBC
transfusion was avoided in 29% of patients in the fibri-
nogen-PCC group, and these patients received no trans-
fusion of any allogeneic blood products. In contrast,
RBC transfusion was avoided in only 3% of patients in
the FFP group. Transfusion of platelet concentrate was
avoided in 91% of patients in the fibrinogen-PCC group,
compared with 56% in the FFP group. In our trauma
centre, TEM-guided haemostatic therapy with fibrinogen
concentrate and PCC has been associated with a conti-
nuing decrease in the use of all types of allogeneic
blood products.
Figure 1 Platelet concentrate and red blood cell (RBC)
transfusion in the emergency room and during surgery.
*Platelet concentrate transfusion only reported for 371 of 601
patients from the trauma registry of the German Society for Trauma
Surgery (TR-DGU). FFP, fresh frozen plasma; PCC, prothrombin
complex concentrate.
Figure 2 Percentage of patients receiving the indicated amount of haemostatic agent (FFP, fibrinogen concentrate, PCC) in the
emergency room and during surgery. Percentage of patients in brackets. FFP, fresh frozen plasma; PCC, prothrombin complex concentrate.
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products is clearly desirable. The reasons for developing
alternative treatments include intermittent supply
shortages and public concern regarding the safety of
allogeneic blood products [20,21]. Transfusion of FFP,
for instance, carries the risk of transfusion-related lung
injury, transfusion-associated circulatory overload, acute
respiratory distress syndrome, transfusion-related immu-
nomodulation and pathogen transmission [22-24].
Attempts to reduce FFP transfusion are complicated by
the fact that small quantities of FFP are not effective in
correcting coagulopathy [25,26]. Therefore, administra-
tion of FFP in larger amounts should be recommended,
but high doses may have a dilutional effect on haemato-
crit, leading to an increase in RBC transfusion. In con-
trast, our study showed a reduction in RBC and platelet
concentrate transfusion among patients treated with
fibrinogen concentrate and PCCs. High levels of fibrino-
gen increase maximum clot firmness even in patients
with a low platelet count, suggesting possible compensa-
tion for reduced platelet levels (it is hypothesised that
an increased number of fibrin molecules binding a smal-
ler number of platelets may be feasible without compro-
mising clot integrity) [13,14]. The explanation for
reduced RBC transfusion is more uncertain, but coagu-
lation factor concentrates may provide faster cessation
of bleeding and reduced haemodilution compared with
allogeneic blood products. Due to their low volume of
administration, coagulation factor concentrates are also
likely to have a smaller effect on haematocrit. The use
of TEM to diagnose coagulopathy may additionally help
reduce RBC and platelet concentrate transfusion. There
is increasing evidence of the usefulness of viscoelastic
methods for diagnosing trauma-induced coagulopathy
[12,27-29], and several reports have described a reduc-
tion in transfusion requirements following its introduc-
tion to treatment algorithms [30-32].
Our approach to managing coagulopathy in trauma
patients focuses on the use of fibrinogen concentrate
and PCC, which are quicker to administer than allo-
geneic blood products. Several groups have suggested
that reducing the time to administer haemostatic ther-
apy may improve patient outcomes [8-10]. Our group
recently described an algorithm of goal-directed coagu-
lation therapy with fibrinogen and PCC in major trauma
patients [12], and in that study 52% of patients received
the first dose of fibrinogen concentrate within the first
hour, most of them within 30 minutes. In contrast, in a
study published by Snyder et al., the first unit of FFP
was typically administered at a median of 93 minutes
after arrival at the ER [8]. Such delay may be related to
the need for blood group matching, thawing and warm-
ing of FFP before administration (thawing and warming
usually take about 30 minutes). It may be possible to
address this delay, for example by storing thawed
plasma for immediate application [33]. The use of pre-
defined transfusion packages has also been described
[34]. Most trauma centres use defined transfusion
Figure 3 Distribution of transfusion ratios in the FFP and fibrinogen-PCC groups (data are for treatment in the emergency room and
during surgery). The line shown on each graph represents the median ratio (FFP:RBC 1; fibrinogen:RBC 0.9; PCC [in hundreds of units]:RBC 1.6).
FFP, fresh frozen plasma; PCC, prothrombin complex concentrate.
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FFP. Unfortunately, thawing FFP in advance may have
negative consequences, because unused thawed units
must be discarded. To reduce apparent wastage, physi-
cians may be tempted to overuse FFP. This tendency
must be considered in the context of today’s economic
and administrative pressures, because the costs of blood
products are high and often underestimated [35]. The
time to infuse medication is another consideration. In
general, it is recommended that one unit of FFP is
administered over a period of about 30 minutes. In con-
trast, typical doses of fibrinogen concentrate and PCC
may be administered in less than 10 minutes [16,36],
and plasma levels of the coagulation factors adminis-
tered rise rapidly after infusion.
This study was not designed to establish whether TEM-
guided haemostatic therapy with fibrinogen concentrate
and PCC improves mortality. Large numbers of patients
would be required to provide statistically robust evidence
on mortality [37]. We nevertheless report an encouraging
trend towards lower mortality in the fibrinogen-PCC
group compared with the FFP group: 7.5% versus 10.0%
(P = 0.69). One factor likely to affect survival is the speed
of administration of haemostatic therapy - as discussed
above, TEM-guided haemostatic therapy with fibrinogen
concentrate and PCC may be advantageous from that
point of view. The quantity of fibrinogen administered
may also affect mortality rates. Stinger et al.r e p o r t e d
correlations between the amount of fibrinogen adminis-
tered and blood loss and survival in severely bleeding
patients from the Iraq war [38]. Successful haemostatic
therapy with fibrinogen concentrate has been described
in other settings involving extensive surgery and blood
loss (e.g., cardiovascular surgery) [39-41]. Successful use
of PCC to treat acquired coagulopathy in the periopera-
tive setting has previously been reported, albeit in limited
numbers of patients [11,12,42,43]. Animal experiments
have suggested that PCC may be more effective than FFP
in the trauma setting [44], whereas Austrian guidelines
recommend PCC administration in bleeding patients if
clotting time measured by thrombelastography (TEG)/
TEM is prolonged [45]. In the present study, PCC was
administered to treat bleeding when clotting time in the
EXTEM assay was prolonged.
The study inclusion criteria aimed at minimise
between-group differences in patient characteristics. The
choice of 1 g fibrinogen/500 U PCC as inclusion criteria
was based on practical therapy. The minimum amount
of fibrinogen concentrate administered in clinical prac-
tice is 1 g, and patients from the STC were eligible for
inclusion in the study once they had received this dose.
Similarly, the minimum dose of PCC was 500 U. We
chose 2 units of FFP as the criterion for the comparator
group because this dose should contain approximately
1 g of fibrinogen [4], thus enabling comparison with the
fibrinogen-PCC group.
The data analysis revealed some between-group differ-
ences in patient characteristics, and these are worthy of
consideration. Although ISS, TRISS, RISC and AIS for
abdomen and extremity were not significantly different,
there was a significant trend towards more severe head
and chest trauma in the FFP-group. Surprisingly, how-
ever, the score predicting massive transfusion (TASH)
was higher in the fibrinogen-PCC group. Furthermore, it
is difficult to estimate whether trauma-induced coagulo-
pathy related to hypoperfusion was more pronounced in
either of these two groups. On the one hand, blood
pressure was significantly lower in the fibrinogen-PCC
group, and base deficit was non-significantly lower in
this group. On the other hand, both PT (expressed as a
percentage) and platelet count were higher in the FFP
group (P not significant for platelet count). Had hypo-
perfusion been more pronounced in the fibrinogen-PCC
group, the significantly lower transfusion rates would
appear even more encouraging.
The present study has several limitations. Data for the
fibrinogen-PCC group were collected retrospectively from
only one centre. TR-DGU data are collected via standar-
dised forms from trauma centres throughout central Eur-
ope. Although only the main parameters of trauma
management and patient outcome are reported and the
collection of data was carefully checked, there may be
some reporting bias. Furthermore, for some patients
included in the study, the data were incomplete - particu-
larly regarding platelet concentrate transfusion. It cannot
be ruled out that some centres providing data to the TR-
DGU may be using TEM sporadically. As there are cur-
rently no publications on the use of TEM in these centres,
the impact on our results is difficult to estimate. The pre-
sent study did not evaluate any safety aspects, such as
thromboembolic or infectious complications. The impor-
tant difference observed in LOS in the hospital between
the two groups, although encouraging, may be influenced
by local patient management protocols. A prospective
study would be needed to confirm which therapeutic
approach offers the more favourable outcome.
Conclusions
In the present study, TEM-guided haemostatic therapy
with fibrinogen concentrate and PCC reduced the expo-
sure of trauma patients to allogeneic blood products. To
improve current transfusion practice, the potential role
of coagulation factor concentrates in achieving haemos-
tasis rapidly among trauma patients must be considered.
Key messages
￿ In attempting to reduce transfusion of allogeneic
blood products, new therapeutic options are being
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trauma patients.
￿ The present study compared transfusion of RBC
and platelet concentrate in patients receiving either
TEM-guided haemostatic therapy with fibrinogen
concentrate and PCC, or standard FFP-based
therapy.
￿ RBC transfusion was avoided in 29% of patients in
the fibrinogen-PCC group, and these patients
received no transfusion of any allogeneic blood pro-
ducts. In contrast, RBC transfusion was avoided in
only 3% of patients in the FFP group.
￿ Transfusion of platelet concentrate was avoided in
91% of patients in the fibrinogen-PCC group, com-
pared with 56% in the FFP group.
￿ TEM-guided haemostatic therapy with fibrinogen
concentrate and PCC reduced the exposure of
trauma patients to allogeneic blood products.
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